CSF3 and hematologic disorder: Our results encouragingly demonstrated that patients with hematologic malignancies receiving G-CSF-mobilized BM integrated with PBSCs harvests in HLA3/6-matched setting had resemble outcomes regardless of relapse, TRM and survival, when compared with patients only receiving G-CSF-primed PBSCs in HLA4/6-matched HSCT.